Mga Batayang Estadistika
| CIK | 1493712 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to StimCell Energetics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended:May 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11- |
|
| September 2, 2025 |
Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the "Lender") Loan Agreement dated March 25, 2025 LOAN AGREEMENT THIS LOAN AGREEMENT (the "Agreement") dated this 25th day of March, 2025 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the "Lender") OF THE FIRST PART AND StimCell Energetics, Inc. |
|
| September 2, 2025 |
AMENDMENT TO LINE OF CREDIT AGREEMENT Amendment to the line of credit agreement dated July 21, 2025 AMENDMENT TO LINE OF CREDIT AGREEMENT This Amendment (“Amendment”) to the Line of Credit Agreement is made and entered into as of the Effective Date set forth below, by and between: Borrower: StimCell Energetics Inc. |
|
| September 2, 2025 |
Line of credit agreement dated June 20, 2025 LINE OF CREDIT AGREEMENT This Line of Credit Agreement (“Line of Credit”) is made and entered into as of the Effective Date set forth below, by and between: Lender: Richard Jeffs, an individual with an address at 11750 Fairtide Road, Ladysmith, BC V9G 1K5 (“Lender “), AND Borrower: Stimcell Energetics Inc. |
|
| September 2, 2025 |
Loan Agreement dated March 20, 2025 LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 20th day of March, 2025 BETWEEN: David M. |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Stimcell Energetics Inc. (Exact na |
|
| April 14, 2025 |
LINE OF CREDIT AGREEMENT This Line of Credit Agreement (“Line of Credit”) is made and entered into as of the Effective Date set forth below, by and between: Lender: Richard Jeffs, an individual with an address at 11750 Fairtide Road, Ladysmith, BC V9G 1K5 (“Lender “), AND Borrower: StimCell Energetics Inc. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Stimcell Energetics Inc. (Exact name of registrant as specified |
|
| April 14, 2025 |
LINE OF CREDIT AGREEMENT This Line of Credit Agreement (“Line of Credit”) is made and entered into as of the Effective Date set forth below, by and between: Lender: Susan Jeffs, an individual with an address at 11750 Fairtide Road, Ladysmith, BC V9G 1K5 (“Lender “), AND Borrower: StimCell Energetics Inc. |
|
| March 28, 2025 |
DIGITAL MARKETING SERVICES AGREEMENT DIGITAL MARKETING SERVICES AGREEMENT Dated: March 18, 2025 (the “Effective Date”). |
|
| March 28, 2025 |
StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the engagement of Independent Investor Relations Consultant Vancouver, BC – March 26, 2025 – StimCell Energetics Inc. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2025 STIMCELL ENERGETICS INC. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 28, 2025 |
REGULATION D SUBSCRIPTION AGREEMENT DEBT SETTLEMENT U.S. RESIDENTS ONLY THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, (THE “ACT”) OR ANY APPLICABLE STATE SECURITIES LAWS. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2025 STIMCELL ENERGETICS INC. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 27, 2025 |
StimCell Energetics Partners with ADM Tronics to Redesign eBalance® Microcurrent Device for Home Use Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers VANCOUVER, BC – February 25, 2025 – StimCell Energetics Inc. |
|
| January 14, 2025 |
LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 12th day of November, 2024 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the “Lender”) OF THE FIRST PART AND StimCell Energetics, Inc. |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Stimcell Energetics Inc. (Exact name of registrant as specified |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2025 STIMCELL ENERGETICS INC. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File |
|
| January 8, 2025 |
StimCell Energetics Inc. Signs Marketing Agreement with Think Ink Marketing StimCell Energetics Inc. Signs Marketing Agreement with Think Ink Marketing Vancouver, BC, January 8, 2025, StimCell Energetics Inc. (OTC: STME) (“StimCell”, or the “Company”) a biotech company targeting cellular energy to promote anti-aging, longevity and general wellness, announces that it has signed an agreement with Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to provide publi |
|
| November 5, 2024 |
STIMCELL ENERGETICS INC. (formerly Cell MedX Corp.) OTC PINK: CMXC FOR IMMEDIATE RELEASE November 4, 2024 StimCell Energetics Inc. (formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding Vancouver, BC, November 4, 2024, StimCell Energetics Inc. (formerly “Cell MedX Corp.”) (OTC Pink: CMXC) (“StimCell”, or the “Company”) a biotech company targeting cellular energy to promote a |
|
| November 5, 2024 | ||
| November 5, 2024 | ||
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 1, 2024 STIMCELL ENERGETICS INC. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its cha |
|
| August 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of reg |
|
| April 15, 2024 |
LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 4th day of January, 2024 BETWEEN: Sam Ahdoot of 13077 Bluff Creek Drive, Playa Vista, CA, 90094, USA (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. |
|
| April 15, 2024 |
LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 4th day of January, 2024 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its c |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2024 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| April 4, 2024 | ||
| March 19, 2024 |
Cell MedX Corp. Closes Private Placement Financing CELL MEDX CORP. OTC PINK: CMXC FOR IMMEDIATE RELEASE MARCH 19, 2024 Cell MedX Corp. Closes Private Placement Financing Vancouver, BC, March 19, 2024, Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces that it |
|
| March 19, 2024 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 12, 2024 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐Preliminary Information Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒Definitive Information Statement CellMedX Corp. (Name of Registrant as Specified in |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 28, 2024 |
Cell MedX Corp. Announces Resignation of Director CELL MEDX CORP. OTC PINK: CMXC FOR IMMEDIATE RELEASE FEBRUARY 28, 2024 Cell MedX Corp. Announces Resignation of Director Vancouver, BC, February 28, 2024, Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces th |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒Preliminary Information Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐Definitive Information Statement CellMedX Corp. (Name of Registrant as Specified in |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its c |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2023 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| December 19, 2023 |
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement CELL MEDX CORP. OTC PINK: CMXC FOR IMMEDIATE RELEASE DECEMBER 19, 2023 Cell MedX Corp. Announces New CEO and Directors and Debt Settlement Vancouver, BC, December 19, 2023, Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announce |
|
| November 27, 2023 |
CELL MEDX CORP. ANNOUNCES FULL REVOCATION OF BRITISH COLUMBIA CEASE TRADE ORDER CELL MEDX CORP. OTC PINK: CMXC FOR IMMEDIATE RELEASE NOVEMBER 27, 2023 CELL MEDX CORP. ANNOUNCES FULL REVOCATION OF BRITISH COLUMBIA CEASE TRADE ORDER Vancouver, BC, November 27, 2023, Cell MedX Corp. (“Cell MedX” or the “Company”) (OTCPink: CMXC) announces that on November 22, 2023, the British Columbia Securities Commission (the “BCSC”) issued an order revoking the Cease Trade Order previously i |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2023 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| November 13, 2023 |
Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer CELL MEDX CORP. OTC PINK: CMXC FOR IMMEDIATE RELEASE NOVEMBER 9, 2023 Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer Vancouver, BC, November 9, 2023, Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote gene |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2023 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its cha |
|
| September 7, 2023 |
CMXC / Cell MedX Corp / Vahabzadeh Amir - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Cell MedX Corp. COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 15115X 107 (CUSIP Number) AMIR VAHABZADEH 1825 West King Edward Avenue Vancouver, BC V6J 2W3 (604) 662-3289 (Name, Address and Telephone Number of Person Authorized to Rece |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of reg |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended:May 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its c |
|
| June 29, 2023 |
Loan Agreement dated Maya 18, 2023, among Cell MedX Corp. and Sam Ahdoot LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 18th day of May, 2023 BETWEEN: Sam Ahdoot of 13077 Bluff Creek Drive, Playa Vista, CA, 90094, USA (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Borrower”) OF THE SECOND PART IN CONSIDERATION O |
|
| June 29, 2023 |
Loan Agreement dated May 16, 2023, among Cell MedX Corp. and Amir Vahabzadeh LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 16th day of May, 2023 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Borrower”) OF THE SECOND PART IN |
|
| May 19, 2023 |
EX-10.67 2 cmxcex1067.htm LOAN AGREEMENT DATED APRIL 11, 2023, AMONG CELL MEDX CORP. AND AMIR VAHABZADEH LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 11th day of April, 2023 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Bo |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specified in its c |
|
| May 19, 2023 |
Loan Agreement dated April 25, 2023, among Cell MedX Corp. and David Jeffs LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 25th day of April, 2023 BETWEEN: David M. Jeffs of 2615 15th Avenue West, Vancouver, BC V6K 2Z6, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Borrower”) OF THE SECOND PART IN CONSIDE |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specifi |
|
| April 7, 2023 |
LOAN AGREEMENT January 30, 2023 Loan Agreement dated January 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs LOAN AGREEMENT January 30, 2023 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CA$7,500 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on January 30, 2023. As per r |
|
| April 7, 2023 |
Loan Agreement and Note Payable dated May 31, 2022, among Cell MedX (Canada) Corp. |
|
| April 7, 2023 |
LOAN AGREEMENT September 2, 2022 Loan Agreement dated September 2, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs LOAN AGREEMENT September 2, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CA$1,800 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on September 2, 2022. As pe |
|
| April 7, 2023 |
LOAN AGREEMENT November 3, 2022 Loan Agreement dated November 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs LOAN AGREEMENT November 3, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$14,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on November 3, 2022. As per |
|
| April 7, 2023 |
Loan Agreement and Note Payable dated June 27, 2022, among Cell MedX (Canada) Corp. |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of reg |
|
| April 7, 2023 |
LOAN AGREEMENT November 28, 2022 EX-10.62 9 cmxcex1062.htm LOAN AGREEMENT DATED NOVEMBER 28, 2022, AMONG CELL MEDX (CANADA) CORP. AND RICHARD JEFFS LOAN AGREEMENT November 28, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$23,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds |
|
| April 7, 2023 |
Loan Agreement dated January 24, 2023, among Cell MedX Corp. and Amir Vahabzadeh LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 24th day of January, 2023 BETWEEN: Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Borrower”) OF THE SECOND |
|
| April 7, 2023 |
LOAN AGREEMENT September 9, 2022 Loan Agreement dated September 6, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs LOAN AGREEMENT September 9, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$19,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on September 9, 2022. As |
|
| April 7, 2023 |
LOAN AGREEMENT December 30, 2022 Loan Agreement dated December 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs LOAN AGREEMENT December 30, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$27,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 30, 2022. As |
|
| April 7, 2023 |
EX-10.53 5 cmxcex1053.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JULY 28, 2022, AMONG CELL MEDX (CANADA) CORP. AND RICHARD JEFFS LOAN AGREEMENT July 28, 2022 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$18,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced |
|
| April 7, 2023 |
Loan Agreement and Note Payable dated April 28, 2022, among Cell MedX (Canada) Corp. |
|
| April 7, 2023 |
LIST OF SIGNIFICANT SUBSIDIARIES List of Significant Subsidiaries LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| April 7, 2023 |
Loan Agreement dated January 24, 2023, among Cell MedX Corp. and David Jeffs LOAN AGREEMENT THIS LOAN AGREEMENT (the “Agreement”) dated this 24th day of January, 2023 BETWEEN: David M. Jeffs of 2615 15th Avenue West, Vancouver, BC V6K 2Z6, Canada (the “Lender”) OF THE FIRST PART AND Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA (the “Borrower”) OF THE SECOND PART IN CON |
|
| October 18, 2022 |
LOAN AGREEMENT October 3, 2022 LOAN AGREEMENT October 3, 2022 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$19,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 3, 2022. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cel |
|
| October 18, 2022 |
LOAN AGREEMENT October 11, 2022 LOAN AGREEMENT October 11, 2022 THIS LOAN AGREEMENT (the ?Agreement?) is entered into as of the 11th day of October, 2022 (the ?Effective Date?) by and between CELL MEDX CORP. |
|
| October 18, 2022 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 11, 2022 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| October 18, 2022 |
LOAN AGREEMENT October 11, 2022 LOAN AGREEMENT October 11, 2022 THIS LOAN AGREEMENT (the ?Agreement?) is entered into as of the 11th day of October, 2022 (the ?Effective Date?) by and between CELL MEDX (CANADA) CORP. |
|
| October 18, 2022 |
LOAN AGREEMENT October 11, 2022 LOAN AGREEMENT October 11, 2022 THIS LOAN AGREEMENT (the ?Agreement?) is entered into as of the 11th day of October, 2022 (the ?Effective Date?) by and between CELL MEDX CORP. |
|
| October 18, 2022 |
LOAN AGREEMENT October 11, 2022 LOAN AGREEMENT October 11, 2022 THIS LOAN AGREEMENT (the ?Agreement?) is entered into as of the 11th day of October, 2022 (the ?Effective Date?) by and between CELL MEDX (CANADA) CORP. |
|
| October 18, 2022 |
Cell MedX Amends Loan Agreements, Provides Update on Financing and Regulatory Compliance CELL MEDX CORP. OTCPINK: CMXC FOR IMMEDIATE RELEASE OCTOBER 18, 2022 Cell MedX Amends Loan Agreements, Provides Update on Financing and Regulatory Compliance Carson City, Nevada, October 18, 2022, Cell MedX Corp. (OTCPINK: CMXC) (?Cell MedX? or the ?Company?), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote gen |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended:May 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transiti |
|
| April 27, 2022 |
Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE APRIL 27, 2022 Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director Carson City, Nevada, April 27, 2022, Cell MedX Corp. (OTCQB: CMXC) (?Cell MedX? or the ?Company?), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to annou |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 25, 2022 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NV 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| April 11, 2022 |
LOAN AGREEMENT March 29, 2022 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CAD$50,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on March 29, 2022. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cell |
|
| April 11, 2022 |
LOAN AGREEMENT December 30, 2021 EX-10.46 2 cmxcex1046.htm LOAN AGREEMENT AND NOTE PAYABLE DATED DECEMBER 30, 2021 LOAN AGREEMENT December 30, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$25,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 30, 2021. The Borrow |
|
| April 11, 2022 |
LOAN AGREEMENT January 27, 2022 LOAN AGREEMENT January 27, 2022 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$25,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on January 27, 2022. As per request of the Borrower, the Lender transferred the Principal Sum into the account of C |
|
| April 11, 2022 |
LOAN AGREEMENT February 24, 2022 LOAN AGREEMENT February 24, 2022 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$31,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on February 24, 2022. As per request of the Borrower, the Lender transferred the Principal Sum into the account of |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 28, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as speci |
|
| January 12, 2022 |
LOAN AGREEMENT October 7, 2021 LOAN AGREEMENT October 7, 2021 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$15,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 7, 2021. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cel |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as speci |
|
| January 12, 2022 |
LOAN AGREEMENT October 26, 2021 EX-10.43 3 cmxcex1043.htm LOAN AGREEMENT OCTOBER 26, 2021 LOAN AGREEMENT October 26, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$35,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 26, 2021. As per request of the Borrower, the |
|
| January 12, 2022 |
LOAN AGREEMENT November 29, 2021 EX-10.45 5 cmxcex1045.htm LOAN AGREEMENT NOVEMBER 29, 2021 LOAN AGREEMENT November 29, 2021 Brad Hargreaves (the “Lender”) of 904-1616 Bayshore Drive, Vancouver, BC V6G 3L1. advanced CDN$7,500 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on November 29, 2021. The Borrower agrees to repay the Principal Su |
|
| January 12, 2022 |
LOAN AGREEMENT November 24, 2021 EX-10.44 4 cmxcex1044.htm LOAN AGREEMENT NOVEMBER 24, 2021 LOAN AGREEMENT November 24, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$35,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on November 24, 2021. The Borrower agrees to repay the |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as specifi |
|
| October 14, 2021 |
424B3 1 cmxc424b3.htm PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT NO. 4 Filed Pursuant to Rule 424(b)(3) To Prospectus dated March 12, 2021 Registration No. 333-253872 PROSPECTUS 6,337,000 Shares of Common Stock This Prospectus Supplement supplements the Prospectus dated March 12, 2021 (the “Prospectus”), relating to the offer and sale by the selling security holders identified in the Prospectus o |
|
| October 12, 2021 |
PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) To Prospectus dated March 12, 2021 Registration No. 333-253872 PROSPECTUS 6,337,000 Shares of Common Stock This Prospectus Supplement supplements the Prospectus dated March 12, 2021 (the “Prospectus”), relating to the offer and sale by the selling security holders identified in the Prospectus of up to 6,337,000 shares of common stock of |
|
| August 30, 2021 |
LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| August 30, 2021 |
EX-10.37 3 cmxcex1037.htm LOAN AGREEMENT AND NOTE PAYABLE DATED APRIL 15, 2021 LOAN AGREEMENT April 15, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on April 15, 2021. The Borrower agrees to repay the |
|
| August 30, 2021 |
EX-10.38 4 cmxcex1038.htm LOAN AGREEMENT AND NOTE PAYABLE DATED MAY 18, 2021 LOAN AGREEMENT May 18, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$50,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on May 18, 2021. The Borrower agrees to repay the Princi |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of reg |
|
| August 30, 2021 |
EX-10.41 5 cmxcex1041.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JUNE 22, 2021 LOAN AGREEMENT June 22, 2021 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$34,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on June 22, 2021. As per request of the |
|
| August 30, 2021 |
LOAN AGREEMENT March 29, 2021 Susan Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$15,000 (the ?Principal Sum?) to Cell MedX (Canada) Corp. |
|
| May 27, 2021 |
424B3 1 cmxc424b3.htm PROSPECTUS SUPPLEMENT PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) To Prospectus dated March 12, 2021 Registration No. 333-253872 PROSPECTUS 6,337,000 Shares of Common Stock This Prospectus Supplement supplements the Prospectus dated March 12, 2021 (the “Prospectus”), relating to the offer and sale by the selling security holders identified in the Prospectus o |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2021 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 26, 2021 |
INDEPENDENT CONTRACTORS SERVICES AGREEMENT EX-10.2 3 cmxcex102.htm INDEPENDENT CONTRACTOR SERVICES AGREEMENT Exhibit 10.2 INDEPENDENT CONTRACTORS SERVICES AGREEMENT This Independent Contractor Services Agreement (the “Agreement”) is effective this day of May 24, 2021, and is made by and between Cell MedX Corp. (the “Company”), with an address at 123 West Nye Ln., Suite 446, Carson City, NV 89706 and Jim MacFarlane D.B.A. Griffith Armada Ca |
|
| May 26, 2021 |
Exhibit 99.1 CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE MAY 26, 2021 Cell MedX Corp. Converts Debt to Shares, Closes Non-brokered Private Placement Financing, and Engages Investor Relations Consultants Carson City, Nevada, May 26, 2021, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (?Cell MedX? or the ?Company?), a biotech company focusing on the discovery, development and commercializatio |
|
| May 26, 2021 |
INDEPENDENT CONTRACTORS SERVICES AGREEMENT EX-10.1 2 cmxcex101.htm INDEPENDENT CONTRACTOR SERVICES AGREEMENT Exhibit 10.1 INDEPENDENT CONTRACTORS SERVICES AGREEMENT This Independent Contractor Services Agreement (the “Agreement”) is effective this 24th day of May, 2021, and is made by and between Cell MedX Corp. (the “Company”), with an address at 123 West Nye Ln., Suite 446, Carson City, NV 89706 and Howard Isaacs of [redacted], and Richa |
|
| April 9, 2021 |
Quarterly Report - CELL MEDX CORP. - FORM 10-Q SEC FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 28, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as speci |
|
| April 9, 2021 |
EX-10.32 2 cmxcex1032.htm LOAN DECEMBER 14, 2020 LOAN AGREEMENT December 14, 2020 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$25,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 14, 2020. The Borrower agrees to repay the Principal Su |
|
| April 9, 2021 |
LOAN AGREEMENT December 23, 2020 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$7,500 (the ?Principal Sum?) to Cell MedX (Canada) Corp. (the ?Borrower?) of 820 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on December 23, 2020. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and |
|
| April 9, 2021 |
PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) To Prospectus dated March 12, 2021 Registration No. 333-253872 PROSPECTUS 6,337,000 Shares of Common Stock This Prospectus Supplement supplements the Prospectus dated March 12, 2021 (the ?Prospectus?), relating to the offer and sale by the selling security holders identified in the Prospectus of up to 6,337,000 shares of common stock of |
|
| April 9, 2021 |
LOAN AGREEMENT January 21, 2021 Rain Communications Corp. (the ?Lender?) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$45,000 (the ?Principal Sum?) to Cell MedX Corp. (the ?Borrower?) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 21, 2021. The Borrower agrees to repay the Principal Sum on demand, together wi |
|
| April 9, 2021 |
EX-10.35 5 cmxcex1035.htm LOAN FEBRUARY 16, 2021 LOAN AGREEMENT February 16, 2021 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on February 16, 2021. The Borrower agree |
|
| March 15, 2021 |
6,337,000 Shares of Common Stock 424B3 1 cmxc424b3.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-253872 PROSPECTUS 6,337,000 Shares of Common Stock We are registering 6,337,000 shares of common stock for resale by the selling security holders (the “Selling Security Holders”) listed in this Prospectus (the “Offering”), consisting of 1,206,000 shares previously issued by the Company and 5,131,000 sh |
|
| March 10, 2021 |
CORRESP 1 filename1.htm March 10, 2021 VIA ELECTRONIC SUBMISSION THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Taylor Beech Dear Sirs/Mesdames: RE: CELL MEDX CORP. (the “Company”) - SEC File No. 333-253872 - Registration Statement on Form S-1 Pursuant to Rule 461 under the Securities Act of 1933, as amended, th |
|
| March 4, 2021 |
Registration Statement - REGISTRATION STATEMENT S-1 1 cmxcs1.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March , 2021 File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cell MedX Corp. (Exact name of Registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 5900 |
|
| January 14, 2021 |
EX-10.30 2 cmxcex1030.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 2, 2020, AMONG CELL MEDX CORP. AND RAIN COMMUNICATIONS CORP. LOAN AGREEMENT September 2, 2020 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$6,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson C |
|
| January 14, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as s |
|
| January 14, 2021 |
LOAN AGREEMENT October 26, 2020 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$40,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on October 26, 2020. The Borrower agrees to repay the Principal Sum on demand, together wi |
|
| October 15, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as spe |
|
| September 15, 2020 |
LOAN AGREEMENT THIS LOAN AGREEMENT (this "Agreement") dated this 3rd day of July, 2020 BETWEEN: David M. |
|
| September 15, 2020 |
LOAN AGREEMENT August 31, 2020 LOAN AGREEMENT August 31, 2020 Tradex Capital Corp., (the “Lender”) with an address at 1177 W. Hastings Street, Suite 2288, Vancouver, BC V6E 2K3, advanced USD$65,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on August 31, 2020. The Borrower agrees to repay the Principal Sum on demand, together with i |
|
| September 15, 2020 |
LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| September 15, 2020 |
LOAN AGREEMENT April 13, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$55,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| September 15, 2020 |
10-K 1 cmxc10k.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-545 |
|
| August 31, 2020 |
NT 10-K 1 cmxcnt10k.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: May 31, 2020 [ ] Transition Report on Form 10-K [ ] Transition Report o |
|
| August 4, 2020 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2020 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 4, 2020 |
Cell MedX Corp. (CMXC) Closes Non-Brokered Private Placement Financing EX-99.2 3 cmxcex992.htm NEWS RELEASE DATED AUGUST 4, 2020 CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE ON August 4, 2020 Cell MedX Corp. (CMXC) Closes Non-Brokered Private Placement Financing Carson City, Nevada, August 4, 2020, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-t |
|
| August 4, 2020 |
Cell MedX Corp. (CMXC) Announces a Non-Brokered Private Placement Financing CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE ON April 17, 2020 Cell MedX Corp. (CMXC) Announces a Non-Brokered Private Placement Financing Carson City, Nevada, April 17, 2020, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, ann |
|
| June 11, 2020 |
8-K 1 cmxc8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2020 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorpor |
|
| June 11, 2020 |
Cell MedX Corp. Receives Quality Management System ISO 13485:2016 MDSAP CertificatE EX-99.1 2 cmxcex991.htm NEWS RELEASE DATED JUNE 9, 2020 CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE ON JUNE 9, 2020 Cell MedX Corp. Receives Quality Management System ISO 13485:2016 MDSAP CertificatE Carson City, Nevada, June 9, 2020, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a bio-tech company focusing on the discovery, development and commercialization of therapeutic an |
|
| May 7, 2020 |
8-K 1 cmxc8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2020 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorpora |
|
| April 29, 2020 |
CMXC / Cell MedX Corp. / JEFFS RICHARD - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Cell MedX Corp. COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 15115X 107 (CUSIP Number) RICHARD NORMAN JEFFS 11750 Fairtide Road Ladysmith, BC, V9G 1K5 Tel: 250 619 0142 (Name, Address and Telephone Number of Person Authorized |
|
| April 14, 2020 |
LOAN AGREEMENT March 4, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| April 14, 2020 |
LOAN AGREEMENT January 31, 2020 EX-10.63 9 cmxcex1063.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JANUARY 31, 2020, AMONG CELL MEDX CORP. AND LONGVIEW INVESTMENT LIMITED LOAN AGREEMENT January 31, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. |
|
| April 14, 2020 |
LOAN AGREEMENT January 6, 2020 LOAN AGREEMENT January 6, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| April 14, 2020 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 cmxc10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 29, 2020 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX |
|
| April 14, 2020 |
LOAN AGREEMENT February 17, 2020 EX-10.65 10 cmxcex1065.htm LOAN AGREEMENT AND NOTE PAYABLE DATED FEBRUARY 17, 2020, AMONG CELL MEDX CORP. AND LONGVIEW INVESTMENT LIMITED LOAN AGREEMENT February 17, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 |
|
| April 14, 2020 |
LOAN AGREEMENT March 25, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| April 14, 2020 |
LOAN AGREEMENT January 9, 2020 LOAN AGREEMENT January 9, 2020 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| April 14, 2020 |
LOAN AGREEMENT December 3, 2019 EX-10.60 6 cmxcex1060.htm LOAN AGREEMENT AND NOTE PAYABLE DATED DECEMBER 3, 2019, AMONG CELL MEDX CORP. AND LONGVIEW INVESTMENT LIMITED LOAN AGREEMENT December 3, 2019 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. |
|
| January 31, 2020 |
Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalanceⓇ Device CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE ON January 30, 2020 Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalanceⓇ Device Carson City, Nevada, January 30, 2020, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote ge |
|
| January 31, 2020 |
Buyback Agreement This agreement (“Agreement”) is entered into between Live Current Media, Inc. |
|
| January 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2020 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 14, 2020 |
LOAN AGREEMENT September 16, 2019 LOAN AGREEMENT September 16, 2019 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$24,450 (the “Principal Sum”) to Cell MedX Corp. |
|
| January 14, 2020 |
CMXC / Cell MedX Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as s |
|
| January 14, 2020 |
LOAN AGREEMENT October 30, 2019 EX-10.59 8 cmxcex1059.htm LOAN AGREEMENT AND NOTE PAYABLE DATED OCTOBER 30, 2019, WITH RAIN COMMUNICATIONS CORP. LOAN AGREEMENT October 30, 2019 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Len |
|
| January 14, 2020 |
LOAN AGREEMENT September 20, 2019 LOAN AGREEMENT September 20, 2019 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$67,975 (the “Principal Sum”) to Cell MedX Corp. |
|
| January 14, 2020 |
LOAN AGREEMENT October 30, 2019 LOAN AGREEMENT October 30, 2019 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$20,500 (the “Principal Sum”) to Cell MedX Corp. |
|
| January 14, 2020 |
LOAN AGREEMENT September 19, 2019 LOAN AGREEMENT September 19, 2019 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$40,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 19, 2019. The Borrower agrees to repay the Principal Sum on demand, togethe |
|
| January 14, 2020 |
LOAN AGREEMENT September 4, 2019 LOAN AGREEMENT September 4, 2019 Longview Investment Limited (the “Lender”) with an address at PO Box 267 Hiberian House, 1136 Leeward Hwy, Providenciales, Turks & Caicos, BVI, advanced USD$19,725 (the “Principal Sum”) to Cell MedX Corp. |
|
| January 14, 2020 |
LOAN AGREEMENT September 6, 2019 LOAN AGREEMENT September 6, 2019 Rain Communications Corp. (the “Lender”) with an address at 1130 West Pender Street, Unit 820, Vancouver, BC V6E 4A4, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 6, 2019. The Borrower agrees to repay the Principal Sum on demand, together |
|
| October 15, 2019 |
CMXC / Cell MedX Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as spe |
|
| September 6, 2019 |
CMXC / Cell MedX Corp. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of |
|
| September 6, 2019 |
LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| August 30, 2019 |
CMXC / Cell MedX Corp. NT 10-K - - FORM 12B-25 NT 10-K 1 cmxcnt10k.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: May 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report o |
|
| June 28, 2019 |
CELL MEDX CORP. OTCQB:CMXC FOR IMMEDIATE RELEASE May 30, 2019 Cell MedX Corp. (CMXC) Arranges a Non-brokered Private Placement Financing Carson City, Nevada, May 30, 2019, Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arrange |
|
| June 28, 2019 |
CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE June 28, 2019 Cell MedX Corp. (CMXC) Closes the First Tranche of its Non-brokered Private Placement Financing Carson City, Nevada, June 28, 2019, Cell MedX Corp. (OTCQB: CMXC), (“Cell MedX” or the “Company”), a bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote gene |
|
| June 28, 2019 |
Regulation FD Disclosure, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2019 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 22, 2019 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 28, 2019 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as s |
|
| April 15, 2019 |
CMXC / Cell MedX Corp. FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: February 28, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Repo |
|
| March 27, 2019 |
Cell MedX signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc. EX-99.1 3 cmxcex991.htm NEWS RELEASE CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE MARCH 27, 2019 Cell MedX signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc. Carson City, Nevada, March 27, 2019, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of the |
|
| March 27, 2019 |
Distribution Agreement This agreement is between Live Current Media, Inc. (“LIVC” or “Distributor”) located at 880 – 50 West Liberty Street, Reno, NV 89501, and Cell MedX Corp. (“CMXC” or “Lessor”) located at 123 W. Nye Ln, Suite 446 Carson City, NV. For purposes of this agreement, LIVC and CMXC are referred to collectively as “the Parties.” Background WHEREAS, CMXC is the manufacturer of a microc |
|
| March 27, 2019 |
8-K 1 cmxc8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incor |
|
| February 5, 2019 |
CMXC / Cell MedX Corp. / JEFFS RICHARD - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Cell MedX Corp. COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 15115X 107 (CUSIP Number) RICHARD NORMAN JEFFS 11750 Fairtide Road Ladysmith, BC, V9G 1K5 Tel: 250 619 0142 (Name, Address and Telephone Number of Person Authorized |
|
| January 14, 2019 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) 10-Q 1 cmxc10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX |
|
| January 14, 2019 |
LOAN AGREEMENT September 13, 2018 LOAN AGREEMENT September 13, 2018 Tradex Capital Corp., (the “Lender”) of 1177 W. Hastings Street, Suite 1920, Vancouver, BC V6E 2K3, advanced CAD$31,200 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on September 13, 2018. The Borrower agrees to repay the Principal Sum on demand, together with interest ca |
|
| December 31, 2018 |
Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE ON DECEMBER 31, 2018 Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants Carson City, Nevada, December 31, 2018, Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that pro |
|
| December 31, 2018 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2018 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 31, 2018 |
CREDIT LINE AGREEMENT Principal - Credit Limit Loan Date Interest $250,000 December 27, 2018 6% per annum compounded monthly Borrower: Cell MedX Corp. |
|
| October 16, 2018 |
CMXC / Cell MedX Corp. AMENDMENT #1 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of |
|
| October 15, 2018 |
EX-10.47 6 cmxcex1047.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JUNE 7, 2018 LOAN AGREEMENT June 7, 2018 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on June 7, 2018. The Borrower agrees to repay the Princi |
|
| October 15, 2018 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as spe |
|
| October 15, 2018 |
LOAN AGREEMENT August 1, 2018 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on August 1, 2018. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded month |
|
| October 15, 2018 |
EX-10.48 7 cmxcex1048.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JULY 3, 2018 LOAN AGREEMENT July 3, 2018 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on July 3, 2018. The Borrower understands that the Princ |
|
| September 13, 2018 |
CMXC / Cell MedX Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of |
|
| September 13, 2018 |
EX-10.45 7 cmxcex1045.htm LOAN AGREEMENT AND NOTE PAYABLE DATED APRIL 5, 2018 EXHIBIT 10.45 LOAN AGREEMENT April 5, 2018 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on April 5, 2018. The Borrower agrees to |
|
| September 13, 2018 |
Intellectual Property Royalty Agreement Intellectual Property Royalty Agreement THIS ROYALTY AGREEMENT, effective as of September 6, 2018 is between Cell MedX Corp. |
|
| September 13, 2018 |
EX-10.49 11 cmxcex1049.htm LETTER OF INTENT DATED FOR REFERENCE SEPTEMBER 10, 2018 Letter of Intent This Letter of Intent (“LOI”) is between Live Current Media, Inc. located at 820 - 1130 West Pender Street, Vancouver, BC V6E 4A4, Canada (“LIVC”), and Cell MedX Corp. located at 123 W. Nye Ln, Suite 446 Carson City, NV (“CMXC”). For purposes of this LOI, LIVC and CMXC are referred to collectively a |
|
| September 13, 2018 |
EX-21.1 2 cmxcex211.htm LIST OF SIGNIFICANT SUBSIDIARIES LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| September 13, 2018 |
Intellectual Property Royalty Agreement EX-10.48 10 cmxcex1048.htm ROYALTY AGREEMENT DATED FOR REFERENCE SEPTEMBER 6, 2018 Intellectual Property Royalty Agreement THIS ROYALTY AGREEMENT, effective as of September 6, 2018 is between Richard N. Jeffs and Cell MedX Corp. a Nevada corporation and or any subsidiaries (“Cell MedX”) Background A. Cell MedX is the owner and developer of microcurrent devices for therapeutic purposes. B. Cell Med |
|
| September 13, 2018 |
EXHIBIT 10.46 LOAN AGREEMENT May 8, 2018 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on May 8, 2018. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compound |
|
| August 30, 2018 |
CMXC / Cell MedX Corp. FORM 12B-25 NT 10-K 1 cmxznt10k.htm FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: May 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report o |
|
| May 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2018 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 7, 2018 |
Dr. Terrance Owen Resigns as CEO of Cell MedX Corp EX-99.1 2 cmxcex991.htm NEWS RELEASE CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE MAY 7th, 2018 Dr. Terrance Owen Resigns as CEO of Cell MedX Corp Carson City, Nevada, May 7, 2018, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therape |
|
| April 16, 2018 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 28, 2018 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as s |
|
| March 26, 2018 |
8-K 1 cmxc8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2018 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incor |
|
| March 26, 2018 |
Cell MedX Corp. Appoints Dr. George Adams as Director EX-99.1 2 cmxcex991.htm NEWS RELEASE CELL MEDX CORP. OTCQB: CMXC, 9CX.MU FOR IMMEDIATE RELEASE March 26, 2018 Cell MedX Corp. Appoints Dr. George Adams as Director Carson City, Nevada, March 26, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX.MU), (“Cell MedX” or the “Company”), an early-stage biotech company focusing on the discovery, development and commercialization of products that promote general wel |
|
| January 16, 2018 |
Product Development Agreement for EX-10.43 2 cmxcex1043.htm PRODUCT DEVELOPMENT AGREEMENT FOR EBALANCE Product Development Agreement for Ebalance between WESTERN ROBOTICS LTD. a British Columbia corporation with offices at #215-12837 76 Avenue, Surrey, B.C., Canada V3W 2V3, hereinafter “Western Robotics”; and CELL MEDX CORP . a Nevada corporation with offices at #446-123 West Nye Ln, Carson City, Nevada, 89706, hereinafter “CELL M |
|
| January 16, 2018 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as s |
|
| December 5, 2017 |
MANAGEMENT CONSULTING AGREEMENT EX-10.1 2 cmxcex101.htm MANAGEMENT CONSULTING AGREEMENT MANAGEMENT CONSULTING AGREEMENT THIS AGREEMENT dated for reference the 1st day of December, 2017. BETWEEN: Cell MedX Corp., a company incorporated under the laws of the State of Nevada, having an address located at 123 W. Nye Ln, Suite 446 Carson City, Nevada 89706. (“hereinafter referred to as the “Company”) AND: Terrance Owen, having an add |
|
| December 5, 2017 |
8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2017 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File |
|
| December 5, 2017 |
Cell MedX Corp. Appoints Dr. Terrance Owen as CEO and Director ex-99.1 CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE December 5, 2017 Cell MedX Corp. Appoints Dr. Terrance Owen as CEO and Director Carson City, Nevada, December 5, 2017, Cell MedX Corp. (OTCQB: CMXC), (?Cell MedX? or the ?Company?), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promot |
|
| October 17, 2017 |
NON-QUALIFIED STOCK OPTION AGREEMENT CELL MEDX CORP. A Nevada Corporation THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY APPLICABLE STATE SECURITIES LAWS. |
|
| October 17, 2017 |
NON-QUALIFIED STOCK OPTION AGREEMENT CELL MEDX CORP. A Nevada Corporation EX-10.58 9 cmxcex1058.htm STOCK OPTION AGREEMENT DATED AUGUST 24, 2017 AMONG CELL MEDX CORP. AND JOHN GIOVANNI DI CICCO THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE REOFFERED FOR SALE OR RESOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION |
|
| October 17, 2017 |
NON-QUALIFIED STOCK OPTION AGREEMENT CELL MEDX CORP. A Nevada Corporation THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE "ACT") OR ANY APPLICABLE STATE SECURITIES LAWS. |
|
| October 17, 2017 |
CMXC / Cell MedX Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant as spe |
|
| October 17, 2017 |
LOAN AGREEMENT July 12, 2017 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on July 12, 2017. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly |
|
| August 29, 2017 |
LOAN AGREEMENT February 14, 2017 EXHIBIT 10.51 LOAN AGREEMENT February 14, 2017 Perla Capital Inc. (the “Lender”) of Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Marshall Islands MH96960, advanced USD$75,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on February 14, 2017. The Borrower agrees to repay the Principal Su |
|
| August 29, 2017 |
EXHIBIT 10.52 LOAN AGREEMENT March 8, 2017 Tradex Capital Corp. (the “Lender”) of 1177 W. Hastings Street, Suite 1920, Vancouver, BC V6E 2K3, advanced CAD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on March 8, 2017. The Borrower agrees to repay the Principal Sum on demand, together with interest |
|
| August 29, 2017 |
EXHIBIT 21.1 LIST OF SIGNIFICANT SUBSIDIARIES Subsidiary Name State of Incorporation Cell MedX (Canada) Corp. British Columbia |
|
| August 29, 2017 |
LOAN AGREEMENT January 11, 2017 EXHIBIT 10.49 LOAN AGREEMENT January 11, 2017 Perla Capital Inc. (the “Lender”) of Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Marshall Islands MH96960, advanced CAD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 11, 2017. The Borrower agrees to repay the Principal Sum |
|
| August 29, 2017 |
EX-10.54 7 cmxcex1054.htm LOAN AGREEMENT AND NOTE PAYABLE DATED MAY 5, 2017 EXHIBIT 10.54 LOAN AGREEMENT May 5, 2017 Tradex Capital Corp. (the “Lender”) of 1177 W. Hastings Street, Suite 1920, Vancouver, BC V6E 2K3, advanced USD$50,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on March 8, 2017. The Bo |
|
| August 29, 2017 |
EXHIBIT 10.53 LOAN AGREEMENT April 18, 2017 Perla Capital Inc. (the “Lender”) of Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Marshall Islands MH96960, advanced USD$150,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on April 18, 2017. The Borrower agrees to repay the Principal Sum on |
|
| August 29, 2017 |
LOAN AGREEMENT January 13, 2017 EXHIBIT 10.50 LOAN AGREEMENT January 13, 2017 Perla Capital Inc. (the “Lender”) of Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Marshall Islands MH96960, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on January 13, 2017. The Borrower agrees to repay the Principal Sum |
|
| August 29, 2017 |
CMXC / Cell MedX Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54500 Cell MedX Corp. (Exact name of |
|
| April 14, 2017 |
LOAN AGREEMENT January 6, 2017 EX-10.46 2 cmxcex1046.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JANUARY 6, 2017 LOAN AGREEMENT January 6, 2017 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on January 6, 2017. The Borrower agrees to repay th |
|
| April 14, 2017 |
Cell MedX QUARTERLY REPORT (Quarterly Report) 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 28, 2017 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registrant |
|
| April 14, 2017 |
LOAN AGREEMENT February 27, 2017 ex-10.48 LOAN AGREEMENT February 27, 2017 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$10,000 (the ?Principal Sum?) to Cell MedX Corp. (the ?Borrower?) of 123 W. Nye Ln, Suite 446, Carson City NV 89706. The Lender advanced the funds on February 27, 2017. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and co |
|
| April 14, 2017 |
LOAN AGREEMENT February 7, 2017 ex-10.47 LOAN AGREEMENT February 7, 2017 Richard N. Jeffs (the ?Lender?) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$15,000 (the ?Principal Sum?) to Cell MedX Corp. (the ?Borrower?) of 123 W. Nye Ln, Suite 446, Carson City NV 89706. The Lender advanced the funds on February 7, 2017. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and comp |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2017 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 28, 2017 |
Cell MedX Corp. Engages Think Ink Marketing EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 24, 2017 CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE FEBRUARY 24th, 2017 Cell MedX Corp. Engages Think Ink Marketing Carson City, Nevada, February 24, 2017, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of th |
|
| February 3, 2017 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D. |
|
| January 30, 2017 |
8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2017 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) |
|
| January 30, 2017 |
Cell MedX Corp. Moves Forward on Strategic Planning CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE JANUARY 30th, 2017 Cell MedX Corp. Moves Forward on Strategic Planning Carson City, Nevada, January 30, 2017, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote |
|
| January 17, 2017 |
Cell MedX 10-Q (Quarterly Report) form10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2016 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registr |
|
| October 17, 2016 |
Cell MedX 10-Q (Quarterly Report) form10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2016 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name of registran |
|
| September 29, 2016 |
ex105.htm Jean Arnett and Brad Hargreaves 904-1616 Bayshore Drive Vancouver BC V6G 3L1 September 26, 2016 Re: Letter agreement outlining terms and conditions to cancel options to acquire up to 17,500,000 common shares of Cell MedX Corp. Dear Mr. Hargreaves and Ms. Arnett: This letter agreement summarizes the mutual understanding and agreement in respect of the cancellation of the options to purcha |
|
| September 29, 2016 |
ex991.htm CELL MEDX CORP. OTCQB: CMXC FOR IMMEDIATE RELEASE SEPTEMBER 29, 2016 Cell MedX Corp. (CMXC) Cancels Options and Appoints a Director Las Vegas, Nevada, September 29, 2016, Cell MedX Corp. (OTCQB: CMXC), (?Cell MedX? or the ?Company?) a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to announc |
|
| September 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2016 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 13, 2016 |
Cell MedX 10-K (Annual Report) 10-K 1 form10k.htm 10-K l;,,,,,,,,,,,,,,,,, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2016 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| September 13, 2016 |
LOAN AGREEMENT June 1, 2016 Tradex Capital Corp., (the “Lender”) of 888 Dunsmuir Street, Suite 1100, Vancouver, BC V6C 3K4, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on June 1, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and comp |
|
| September 13, 2016 |
EX-10.42 6 ex1042.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JUNE 30, 2016, AMONG CELL MEDX CORP., AND RICHARD N. JEFFS. LOAN AGREEMENT June 30, 2016 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$32,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on June 30, 2 |
|
| September 13, 2016 |
LOAN AGREEMENT June 29, 2016 Tradex Capital Corp., (the “Lender”) of 1055 West Hastings Street, Suite #1910, Vancouver, BC, V6E 2E9, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on June 29, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest calculate |
|
| September 13, 2016 |
LIST OF SIGNIFICANT SUBSIDIARIES, EXHIBIT 21 LIST OF SIGNIFICANT SUBSIDIARIES, EXHIBIT 21 Subsidiary Name State of Incorporation Avyonce Cosmedics Inc. British Columbia Cell MedX (Canada) Corp. British Columbia |
|
| September 13, 2016 |
LOAN AGREEMENT April 29, 2016 Richard N. Jeffs (the “Lender”) of Parcela 29, Perales Viejo Vallenar, III Region Chile, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on April 29, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compoun |
|
| September 13, 2016 |
LOAN AGREEMENT August 8, 2016 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$32,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on August 8, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthl |
|
| September 13, 2016 |
LOAN AGREEMENT August 22, 2016 LOAN AGREEMENT August 22, 2016 Tradex Capital Corp., (the “Lender”) of 888 Dunsmuir Street, Suite 1100, Vancouver, BC V6C 3K4, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on August 22, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated an |
|
| September 13, 2016 |
EX-10.40 4 ex1040.htm LOAN AGREEMENT AND NOTE PAYABLE DATED JUNE 2, 2016, AMONG CELL MEDX CORP., AND RICHARD N. JEFFS. LOAN AGREEMENT June 2, 2016 Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced CDN$32,500 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on June 2, 2016 |
|
| August 29, 2016 |
ntform10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54500 CUSIP NUMBER 15115X 107 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: May 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transi |
|
| April 25, 2016 |
CMXC / Cell MedX Corp. / JEFFS RICHARD - SC 13D Activist Investment SC 13D 1 sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CELL MEDX CORP. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE PAR VALUE (Title of Class of Securities) 15115X 107 (CUSIP Number) RICHARD NORMAN JEFFS Perales Viejos 29, Casilla 16 Vallenar, III Region, Atacama, Chile Tel: +56 9 6149 0057 (Name, |
|
| April 14, 2016 |
EX-10.36 6 ex1036.htm LOAN AGREEMENT AND NOTE PAYABLE DATED MARCH 30, 2016, AMONG CELL MEDX CORP., AND TRADEX CAPITAL CORP. LOAN AGREEMENT March 30, 2016 Tradex Capital Corp., (the “Lender”) of 888 Dunsmuir Street, Suite #1100, Vancouver, BC, V6C 3K4, advanced USD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced |
|
| April 14, 2016 |
ex1035.htm LOAN AGREEMENT March 10, 2016 Tradex Capital Corp., (the ?Lender?) of 888 Dunsmuir Street, Suite #1100, Vancouver, BC, V6C 3K4, advanced USD$50,000 (the ?Principal Sum?) to Cell MedX Corp. (the ?Borrower?) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on March 10, 2016. The Borrower agrees to repay the Principal Sum on demand, together with interest ca |
|
| April 14, 2016 |
LOAN AGREEMENT February 4, 2016 EX-10.32 3 ex1032.htm LOAN AGREEMENT AND NOTE PAYABLE DATED FEBRUARY 4, 2016, AMONG CELL MEDX CORP., AND TRADEX CAPITAL CORP. LOAN AGREEMENT February 4, 2016 Tradex Capital Corp., (the “Lender”) of 888 Dunsmuir Street, Suite #1100, Vancouver, BC, V6C 3K4, advanced USD$50,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender adva |
|
| April 14, 2016 |
Cell MedX 10-Q (Quarterly Report) 10-Q 1 form10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended February 29, 2016 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact nam |
|
| April 14, 2016 |
EX-10.33 4 ex1033.htm LOAN AGREEMENT AND NOTE PAYABLE DATED MARCH 2, 2016, AMONG CELL MEDX CORP., AND TRADEX CAPITAL CORP. LOAN AGREEMENT March 2, 2016 Tradex Capital Corp., (the “Lender”) of 888 Dunsmuir Street, Suite #1100, Vancouver, BC, V6C 3K4, advanced USD$75,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced t |
|
| April 14, 2016 |
LOAN AGREEMENT November 5, 2015 ex1030.htm LOAN AGREEMENT November 5, 2015 Tradex Capital Corp., (the ?Lender?) of 1055 West Hastings Street, Suite #1910, Vancouver, BC, V6E 2E9, advanced USD$20,000 (the ?Principal Sum?) to Cell MedX Corp. (the ?Borrower?) of 74 N. Pecos Road, Suite D, Henderson, NV, 89074. The Lender will advance the funds on November 5, 2015. The Borrower agrees to repay the Principal Sum on demand, together w |
|
| April 14, 2016 |
EX-10.37 7 ex1037.htm LOAN AGREEMENT AND NOTE PAYABLE DATED MARCH 31, 2016 AMONG CELL MEDX CORP., AND RICHARD N. JEFFS. LOAN AGREEMENT March 31, 2016 Richard N. Jeffs (the “Lender”) of Parcela 29, Perales Viejo Vallenar, III Region Chile, advanced USD$30,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 2857 Sumter Valley Circle, Henderson, NV 89052. The Lender advanced the funds on |
|
| March 9, 2016 |
ex101.htm THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS, AND ARE PROPOSED TO BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT PROVIDED BY REGULATION S PROMULGATED UNDER THE SECURITIES ACT. UPON ANY SALE, SUCH SECURITIES MAY NOT BE REOFFERED FOR S |
|
| March 9, 2016 |
Cell MedX Corp. Signs a Loan Agreement ex991.htm Cell MedX Corp. Signs a Loan Agreement Las Vegas, Nevada, March 9, 2016, Cell MedX Corp. (OTCQB: CMXC) (?Cell MedX? or the ?Company?), announces that on March 3, 2016 it has entered into a loan agreement (the ?Loan Agreement?) for a loan in the principal amount of $50,000 (the ?Loan?). The Loan matures on March 3, 2017, with principal accumulating interest at a rate of 6% per annum. As a |
|
| March 9, 2016 |
Entry into a Material Definitive Agreement form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : March 3, 2016 CELL MEDX CORP. (Exact name of registrant as specified in its charter) NEVADA 000-54500 38-3939625 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2016 |
-- THE REST OF THIS PAGE IS INTENTIONALLY LEFT BLANK -- CELL MEDX CORP. 74 N. Pecos Road, Suite D Henderson, NV 89074 USA December 4, 2015 CLAUDIO TASSI C/Santiago 15-30 47001 Valladolid Spain BIOFORMED AESTHETIC S.L. C/Santiago 15-30 47001 Valladolid Spain Dear Sirs: Re: Proposed Development Agreement and License Agreement among Cell MedX Corp. (“Cell MedX”), Claudio Tassi (“Tassi”) and Bioformed Aesthetic S.L. (“Bioformed”). [Missing Graphic Referenc |
|
| January 14, 2016 |
CMXC / Cell MedX Corp. 10-Q - Quarterly Report - 10-Q 10-Q 1 form10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2015 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact nam |
|
| January 14, 2016 |
LOAN AGREEMENT December 23, 2015 LOAN AGREEMENT December 23, 2015 Coventry Capital LLC, (the “Lender”) of 1201 Orange Street, Suite 600, Wilmington, DE 19801 advanced USD$150,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| October 15, 2015 |
eBALANCE PROTOTYPE DEVELOPMENT AGREEMENT EX-10.28 11 ex1028.htm EBALANCE PROTOTYPE DEVELOPMENT AGREEMENT DATED OCTOBER 1, 2015 AMONG CELL MEDX CORP., AND CLAUDIO TASSI. eBALANCE PROTOTYPE DEVELOPMENT AGREEMENT THIS AGREEMENT dated effective as of the 1st day of October, 2015 ("Effective Date"). BETWEEN: CLAUDIO TASSI, business person, having an address at C/ Santiago, 15 – 3o, 47001 Valladolid, Spain (hereinafter referred to as “Mr. Tass |
|
| October 15, 2015 |
NON-QUALIFIED STOCK OPTION AGREEMENT CELL MEDX CORP. A Nevada Corporation EX-10.25 8 ex1025.htm STOCK OPTION AGREEMENT DATED SEPTEMBER 23, 2015 AMONG CELL MEDX CORP. AND STEVEN H. BULWA. THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND ARE PROPOSED TO BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT PROVIDED BY REGULATION S PROMULGATED UNDER THE SECURITIES |
|
| October 15, 2015 |
CONSULTING AGREEMENT THIS AGREEMENT dated effective as of the 1st day of September, 2015 ("Effective Date"). |
|
| October 15, 2015 |
LOAN AGREEMENT September 3, 2015 EX-10.23 6 ex1023.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 3, 2015 AMONG CELL MEDX CORP., AND RICHARD N. JEFFS. LOAN AGREEMENT September 3, 2015 Richard N. Jeffs (the “Lender”) of Parcela 29, Perales Viejo Vallenar, III Region Chile, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 74 N. Pecos Road, Suite D, Henderson, NV, 89074. The Lender advanced the f |
|
| October 15, 2015 |
LOAN AGREEMENT September 24, 2015 EX-10.26 9 ex1026.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 24, 2015 AMONG CELL MEDX CORP., AND CITY GROUP LLC. LOAN AGREEMENT September 24, 2015 City Group LLC (the “Lender”) of 1201 Orange Street, Suite 600, Wilmington, DE 19801, advanced total of USD$20,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 74 N. Pecos Road, Suite D, Henderson, NV, 89074. The Lender advanced |
|
| October 15, 2015 |
CELL MEDX CORP. CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EX-3.2 3 ex312.htm CERTIFICATION CELL MEDX CORP. CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Yanika Silina, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ending August 31, 2015 of Cell MedX Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necess |
|
| October 15, 2015 |
LOAN AGREEMENT September 28, 2015 EX-10.27 10 ex1027.htm LOAN AGREEMENT AND NOTE PAYABLE DATED SEPTEMBER 28, 2015 AMONG CELL MEDX CORP., AND RICHARD N. JEFFS. LOAN AGREEMENT September 28, 2015 Richard N. Jeffs (the “Lender”) of Parcela 29, Perales Viejo Vallenar, III Region Chile, advanced USD$25,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 74 N. Pecos Road, Suite D, Henderson, NV, 89074. The Lender advanced th |
|
| October 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 form10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2015 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-54500 Cell MedX Corp. (Exact name |
|
| September 3, 2015 |
LOAN AGREEMENT April 20, 2015 City Group LLC (the “Lender”) of 1201 Orange Street, Suite 600, Wilmington, DE 19801, advanced total of USD$10,000 (the “Principal Sum”) to Cell MedX Corp. |
|
| September 3, 2015 |
CONSULTING AGREEMENT THIS AGREEMENT dated effective as of the 1st day of September, 2014. |
|
| September 3, 2015 |
LOAN AGREEMENT August 12, 2015 LOAN AGREEMENT August 12, 2015 Richard N. Jeffs (the “Lender”) of Parcela 29, Perales Viejo Vallenar, III Region Chile, advanced USD$24,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 74 N. Pecos Road, Suite D, Henderson, NV, 89074. The Lender advanced the funds on August 12, 2015. The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and comp |
